Coverage
-
February 23, 2018
The full Federal Circuit will not review a panel decision that revived a challenge to Amgen's patents for Repatha, an antibody-based cholesterol treatment, according to a decision issued by the appeals court Friday.
7 other articles on this case.
View all »